Nöroimmünoloji Pratiğinde İmmünomodulatör Tedavi Seçenekleri ve Bireysel Tedavi

Matricardi S, Farello G, Savasta S and Verrotti A. Understanding childhood neuroimmune diseases of the central nervous system. Frontiers in Pediatrics 2019; 7: 511.

Cain DW and Cidlowski JA. Immune regulation by glucocorticoids. Nature Reviews Immunology 2017; 17: 233-247.

TAŞKIRDI ED and DÜNDAR NO. İmmünomodulatuar Tedavi ve Nöroimmünolojide Yeni Tedavi Seçenekleri. Turkiye Klinikleri Pediatric Neurology-Special Topics 2023; 4: 279-288.

Macaron G and Willis MA. Concepts of Immune Therapy and Disease Management. Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases 2021: 59-71.

Golumbek P. Pharmacologic agents for pediatric neuroimmune disorders. In: Seminars in pediatric neurology 2010, pp.245-253. Elsevier.

Pranzatelli MR and Tate ED. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. Brain and Development 2016; 38: 439-448.

Lünemann JD, Nimmerjahn F and Dalakas MC. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nature Reviews Neurology 2015; 11: 80-89.

Nosadini M, Mohammad SS, Suppiej A, Sartori S, Dale RC, Group IiNS, et al. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long‐term outcome. Developmental Medicine & Child Neurology 2016; 58: 1180-1192.

Abrantes FF, de MORAES MPM, de Albuquerque Filho JMV, Alencar JMD, Lopes AB, de Rezende Pinto WBV, et al. Immunosuppressors and immunomodulators in Neurology-Part I: a guide for management of patients underimmunotherapy. Arquivos de Neuro-Psiquiatria 2021; 79: 1012-1025.

Padmanabhan A, Connelly‐Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. Journal of clinical apheresis 2019; 34: 171-354.

Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, et al. Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 2001; 50: 349-357.

Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS drugs 2011; 25: 491-502.

Hu MY, Stathopoulos P, O’connor KC, Pittock SJ and Nowak RJ. Current and future immunotherapy targets in autoimmune neurology. Handbook of Clinical Neurology 2016; 133: 511-536.

Konuskan B and Anlar B. Treatment in childhood central nervous system demyelinating disorders. Developmental Medicine & Child Neurology 2019; 61: 1281-1288.

Rommer PS and Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert opinion on pharmacotherapy 2018; 19: 483-498.

Farina C, Weber MS, Meinl E, Wekerle H and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. The Lancet Neurology 2005; 4: 567-575.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J and Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014; 74: 659-674.

Scott LJ. Teriflunomide: a review in relapsing–remitting multiple sclerosis. Drugs 2019; 79: 875-886.

Mills EA, Ogrodnik MA, Plave A and Mao-Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Frontiers in neurology 2018; 9: 5.

Brennan MS, Matos MF, Richter KE, Li B and Scannevin RH. The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes. Scientific reports 2017; 7: 42054.

Blair HA. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs 2019; 79: 1965-1976.

Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New England Journal of Medicine 2006; 355: 1124-1140.

Claes N, Dhaeze T, Fraussen J, Broux B, Van Wijmeersch B, Stinissen P, et al. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PloS one 2014; 9: e111115.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery & Psychiatry 2016; 87: 468-475.

Stuve O, Cravens P, Frohman E, Phillips J, Remington G, Von Geldern G, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72: 396-401.

Ruck T, Bittner S, Wiendl H and Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. International journal of molecular sciences 2015; 16: 16414-16439.

Devonshire V, Phillips R, Wass H, Da Roza G and Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. Journal of Neurology 2018; 265: 2494-2505.

Awad A and Stüve O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Therapeutic advances in neurological disorders 2009; 2: 357-368.

Clardy SL and Smith TL. Therapeutic approach to autoimmune neurologic disorders. CONTINUUM: Lifelong Learning in Neurology 2024; 30: 1226-1258.

Rommer P, Stüve O, Goertsches R, Mix E and Zettl U. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. Journal of neurology 2008; 255: 28-35.

Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism 2008; 58: 2652-2661.

Ellwardt E, Rolfes L, Klein J, Pape K, Ruck T, Wiendl H, et al. Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurology: Neuroimmunology & Neuroinflammation 2020; 7: e719.

Martin E, Aigrot M-S, Grenningloh R, Stankoff B, Lubetzki C, Boschert U, et al. Bruton’s tyrosine kinase inhibition promotes myelin repair. Brain Plasticity 2020; 5: 123-133.

Krämer J, Bar-Or A, Turner TJ and Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology 2023; 19: 289-304.

Scheibe F, Ostendorf L, Reincke SM, Prüss H, Von Bruenneck A-C, Köhnlein M, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. Journal of neurology 2020; 267: 317-323.

Scheibe F, Ostendorf L, Prüss H, Radbruch H, Aschman T, Hoffmann S, et al. Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology. European journal of neurology 2022; 29: 1847-1854.

Palace J, Newsom-Davis J, Lecky B and Group MGS. A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778-1783.

Espiritu AI and Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 2019; 33: 22-32.

Kwong Y-L. Azathioprine: association with therapy-related myelodysplastic syndrome and acute myeloid leukemia. The Journal of rheumatology 2010; 37: 485-490.

Staatz CE and Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Archives of toxicology 2014; 88: 1351-1389.

Villarroel MC, Hidalgo M and Jimeno A. Mycophenolate mofetil: An update. Drugs of today (Barcelona, Spain: 1998) 2009; 45: 521-532.

Wiendl H. Cladribine—an old newcomer for pulsed immune reconstitution in MS. Nature Reviews Neurology 2017; 13: 573-574.

Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. Journal of neurology 2018; 265: 1199-1209.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Multiple Sclerosis Journal 2011; 17: 578-593.

Vollmer T, Stewart T and Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology 2010; 74: S41-S46.

Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74: 1822-1826.

Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, et al. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal 2022; 28: 480-486.

Brandsema JF, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao VK, et al. Eculizumab in Adolescent Patients with Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. Pediatric Neurology 2024.

Lee W-J, Lee S-T, Moon J, Sunwoo J-S, Byun J-I, Lim J-A, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 2016; 13: 824-832.

Lee W-J, Lee S-T, Shin Y-W, Lee HS, Shin H-R, Kim D-Y, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics 2021; 18: 474-487.

Randell RL, Adams AV and Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pediatric Neurology 2018; 86: 66-68.

Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. New England Journal of Medicine 2019; 381: 2114-2124.

Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, et al. Long-term efficacy of satralizumab in AQP4-IgG–seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurology: Neuroimmunology & Neuroinflammation 2022; 10: e200071.

ClinicalTrials.gov. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo), clinicaltrials.gov/study/NCT05503264 (accessed 01.01.2025).

ClinicalTrials.gov. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid), clinicaltrials.gov/study/NCT05271409 (accessed 01.01.2025).

Fritz D, Timmermans WM, van Laar JA, van Hagen PM, Siepman TA, van de Beek D, et al. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurology: Neuroimmunology & Neuroinflammation 2020; 7: e847.

Lagarde S, Villeneuve N, Trébuchon A, Kaphan E, Lepine A, McGonigal A, et al. Anti–tumor necrosis factor alpha therapy (adalimumab) in rasmussen's encephalitis: an open pilot study. Epilepsia 2016; 57: 956-966.

Sota J, Capuano A, Emmi G, Iannone F, Cantarini L, Hatemi G, et al. Therapeutic approach to central nervous system involvement of Behçet's disease. In: Seminars in Arthritis and Rheumatism 2023, p.152206. Elsevier.

Jang Y, Lee WJ, Lee HS, Chu K, Lee SK and Lee ST. Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia 2021; 62: e53-e59.

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. The Lancet 2016; 388: 576-585.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 2017; 88: 842-852.

Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 2017; 88: 2115-2122.